Key clinical point: Risankizumab proved far more efficacious and better tolerated than secukinumab in a head-to-head randomized trial.
Major finding: The PASI 90 response rate at week 52 was 87% in psoriasis patients randomized to risankizumab and 57% with secukinumab.
Study details: This was a phase 3, randomized, head-to-head, international, 52-week trial in 327 patients with moderate-to-severe psoriasis.
Disclosures: The IMMERGE trial was sponsored by AbbVie. The presenter reported receiving research grants from and serving as a consultant to that pharmaceutical company and roughly a dozen others.
FROM AAD 20